Skip to content

Depression: all studies

Page 239 of 1,034: studies 2,381 to 2,390 of 10,336, newest first. Back to the depression overview

Research

Internet-delivered Mindfulness-Based Cognitive Therapy for anxiety and depression in cancer survivors: Predictors of treatment response.

Internet Interventions March 2021 Eva Rames Nissen, Robert Zachariae, Maja O'Connor et al.

The present study investigates possible predictors of treatment response in an Internet-delivered Mindfulness-Based Cognitive Therapy (iMBCT) intervention with therapist support. This iMBCT program, a fully online delivered intervention with asynchronous therapist support, has previously been shown to be efficacious in reducing symptoms of anxiety and depression in women treated for breast...

Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment.

Journal of Affective Disorders March 1, 2021 Roger S McIntyre, Nelson B Rodrigues, Orly Lipsitz et al. 10 citations

BACKGROUND Depression severity and efficacy measurement scales employed for rapid-acting treatments (e.g., ketamine) were initially validated in adults receiving conventional monoamine-based antidepressants. The emergence of rapid-acting antidepressants in psychiatry provides the impetus for outcome measures that have been validated as sensitive to change with rapid-acting treatments. Herein,...

The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review.

Journal of Psychiatric Research March 1, 2021 Joshua D. Di Vincenzo, Ashley N. Siegel, Orly Lipsitz et al. 59 citations

The majority of antidepressant medication trials have focused on adult populations (ages 18-65), with much less research in older and younger populations. Moreover, key differences in the efficacy and safety of antidepressants have been identified between these age groups. Ketamine has emerged as a promising new treatment for treatment resistant depression (TRD). The objective of this review is...

The Effects of Walking Meditation on Depression and Quality of Life among Cancer Patients in a Long-Term Care Hospital

Chonnam Research Institute of Nursing Science February 28, 2021

Purpose: This study aimed to evaluate the effects of walking meditation on cancer patients suffering from depression and their quality of life (QoL) in a long-term care hospital. Methods: This was a quasi-experimental study with a non-equivalent control group and a pretest-posttest design. Forty-nine cancer patients living in a long-term care hospital participated in the study. The experimental...

Mindfulness Training Improves Quality of Life and Reduces Depression and Anxiety Symptoms Among Police Officers: Results From the POLICE Study—A Multicenter Randomized Controlled Trial

Frontiers in Psychiatry February 26, 2021 Marcelo Trombka, Marcelo Demarzo, Daniel Fernando Campos et al.

Background: Police officers' high-stress levels and its deleterious consequences are raising awareness to an epidemic of mental health problems and quality of life (QoL) impairment. There is a growing evidence that mindfulness-based interventions are efficacious to promote mental health and well-being among high-stress occupations. Methods: The POLICE study is a multicenter randomized...

A Mindfulness-Based Brain-Computer Interface to Augment Mandala Coloring for Depression: Protocol for a Single-Case Experimental Design

JMIR Research Protocols February 22, 2021 Claudia Daudén Roquet, Corina Sas

BackgroundThe regular practice of mindfulness has been shown to provide benefits for mental well-being and prevent depression relapse. Technology-mediated interventions can facilitate the uptake and sustained practice of mindfulness, yet the evaluation of interactive systems, such as brain-computer interfaces, has been little explored. ObjectiveThe objective of this paper is to present an...

Ketamine and attentional bias to threat: dynamic causal modeling of magnetoencephalographic connectivity in treatment-resistant depression

medRxiv Preprint Server February 22, 2021 Jessica R. Gilbert, Christina S. Galiano, Allison C. Nugent et al. preprint

The glutamatergic modulator ketamine rapidly reduces depressive symptoms in individuals with treatment-resistant major depressive disorder (MDD) and bipolar disorder. While its underlying mechanism of antidepressant action is not fully understood, modulating glutamatergically-mediated connectivity appears to be a critical component moderating antidepressant response. This double-blind,...

Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment‐resistant depression

Neuropsychopharmacology Reports February 21, 2021 Tomoyuki Nakamura, Masaru Tomita, N. Horikawa et al. 29 citations

Approximately one‐third of patients with major depressive disorder develop treatment‐resistant depression. One‐third of patients with treatment‐resistant depression demonstrate resistance to ketamine, which is a novel antidepressant effective for this disorder. The objective of this study was to examine the utility of resting‐state functional magnetic resonance imaging for the prediction of...

Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial

Brazilian Journal of Psychiatry February 18, 2021 Mara C. Guimarães, Tiago M. Guimarães, Jaime E. C. Hallak et al. 41 citations

OBJECTIVE: Major depressive disorder (MDD) is related to glutamatergic dysfunction. Antagonists of glutamatergic N-methyl-D-aspartate receptor (NMDAR), such as ketamine, have antidepressant properties. Nitrous oxide (N2O) is also a NMDAR antagonist. Thus, this study aimed to evaluate the effects of augmenting antidepressant treatment with N2O. METHODS: This double blind, placebo-controlled...

How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence

Anesthesia & Analgesia February 17, 2021 Peter G. Brindley 49 citations

It is tough to write about psychedelics without a few gratuitous puns. Regardless, Michael Pollan’s “How to Change Your Mind” is definitely “mind expanding” and deserves my “highest” recommendation. Published in 2019, this book comprehensively and presciently covers a topic of increasing interest: whether psychedelic agents can revolutionize mental health. Pollan is not a Medical Doctor but is...

DOI: 10.1213/ane.0000000000005349 (opens in new tab) Psilocybin Counterculture Consciousness Psychic +4